Literature DB >> 9559930

MK-801 reinstates drug-seeking behaviour in cocaine-trained rats.

T J De Vries1, A N Schoffelmeer, R Binnekade, A H Mulder, L J Vanderschuren.   

Abstract

We evaluated the incentive motivational properties of MK-801 by determining its priming effect on drug-seeking behaviour following extinction of cocaine self-administration, an animal model for drug craving. Rats were allowed to self-administrate cocaine (0.5 mg/kg) or saline during 10 daily sessions. MK-801 (0.1-0.25 mg/kg, i.p.) dose-dependently reinstated responding for cocaine following an extinction period of 3 weeks. Responding was selectively enhanced in the previously drug-paired hole and was completely absent in rats with a history of saline self-administration. These data provide evidence for a possible role of NMDA receptors in the incentive motivation underlying cocaine-seeking behaviour. In addition, the ability of MK-801 to elicit drug-seeking behaviour may prove to be a serious drawback for the proposed use of NMDA antagonists in the treatment of drug addiction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559930     DOI: 10.1097/00001756-199803090-00014

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  13 in total

Review 1.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

2.  Neonatal isolation enhances maintenance but not reinstatement of cocaine self-administration in adult male rats.

Authors:  Xiang Yang Zhang; Hayde Sanchez; Priscilla Kehoe; Therese A Kosten
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

3.  When administered into the nucleus accumbens core or shell, the NMDA receptor antagonist AP-5 reinstates cocaine-seeking behavior in the rat.

Authors:  Katie R Famous; Heath D Schmidt; R Christopher Pierce
Journal:  Neurosci Lett       Date:  2007-05-03       Impact factor: 3.046

4.  The NMDA antagonist MK-801 disrupts reconsolidation of a cocaine-associated memory for conditioned place preference but not for self-administration in rats.

Authors:  Travis E Brown; Brian R Lee; Barbara A Sorg
Journal:  Learn Mem       Date:  2008-12-02       Impact factor: 2.460

Review 5.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens.

Authors:  W-K Park; A A Bari; A R Jey; S M Anderson; R D Spealman; J K Rowlett; R C Pierce
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

7.  Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Erik W Gunderson; Heather M Haughey; Xin-Qun Wang; Lei Liu
Journal:  Addict Biol       Date:  2012-10-08       Impact factor: 4.280

8.  Extrasynaptic targeting of NMDA receptors following D1 dopamine receptor activation and cocaine self-administration.

Authors:  Pavel I Ortinski; Jill R Turner; R Christopher Pierce
Journal:  J Neurosci       Date:  2013-05-29       Impact factor: 6.167

Review 9.  The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis.

Authors:  M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.